Servier agreed to acquire KER-0193, a Phase 1-completed potential treatment for Fragile X syndrome, from Kaerus Bioscience for total deal value up to $450M including upfront and development/commercial earn-out payments. First neurology asset acquisition; Orphan and Rare Pediatric drug designations.
Key facts
AnnouncedSep 08, 2025
Deal value$450M
Deal typeAsset Purchase
Therapeutic areaFragile X syndrome
IndicationsFragile X syndrome
Key assetsKER-0193
MechanismBK channel modulator (oral small molecule)